Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,117 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alzheimer's Disease Clear all
Completed Phase 2 Interventional Results available

Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.

NCT00040443
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
CX516, Placebo
Drug
Lead sponsor
RespireRx
Industry
Eligibility
55 Years to 85 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
8
States / cities
Peoria, Arizona • Irvine, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 22, 2026, 6:45 AM EDT
Recruiting Phase 2 Interventional

Open-Label Extension Protocol to SNK01-AD01 Study

NCT07228078
View directory record Official record
Conditions
Alzheimer Disease
Interventions
SNK01
Biological
Lead sponsor
NKGen Biotech, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 22, 2026, 6:45 AM EDT
Recruiting Phase 2 Interventional

Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type

NCT06052254
View directory record Official record
Conditions
Agitation
Interventions
12 cm2 - 2 Active DMTS Patches, 6 cm2 - 1 Active and 1 Placebo DMTS Patches, Placebo - 2 Placebo DMTS Patches
Drug
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Chino, California • Daytona Beach, Florida • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's

NCT00980785
View directory record Official record
Conditions
Alzheimer's Disease, Hypertension
Interventions
Ramipril, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
40 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects

NCT00825084
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 3 Interventional

VITAL - VITamins to Slow ALzheimer's Disease (Homocysteine Study)

NCT00056225
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Folate, Vitamin B6, Vitamin B12
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
38
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Sun City, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2009 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Not applicable Interventional Results available

Vidatalk Communication Application: Usability, Acceptability and Efficacy Study

NCT02921776
View directory record Official record
Conditions
Nonverbal Communication, Critical Illness
Interventions
Aim 1 - VidaTalk - post-extubation, Aim 2 - VidaTalk - intubated, Aim 3 - VidaTalk tablet app, Aim 3 - attention-control with non-VidaTalk tablet
Other · Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 99 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Valproate in Dementia (VALID)

NCT00071721
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Valproate, Placebo
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
55 Years to 90 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
46
States / cities
Sun City, Arizona • Tucson, Arizona • Irvine, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 22, 2026, 6:45 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07169578
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Trontinemab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Sun City, Arizona • Irvine, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Goal Setting to Promote Physical Activity Adherence in Midlife Adults

NCT05980052
View directory record Official record
Conditions
Physical Activity, Exercise
Interventions
Physical Activity
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
45 Years to 65 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing Memory in Mild Cognitive Impairment and Early Stage Alzheimer's Disease

NCT05077826
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
North Coast Medical Activadose II
Device
Lead sponsor
The Mind Research Network
Other
Eligibility
50 Years to 90 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

Effects of Atomoxetine in Mild Cognitive Impairment

NCT01522404
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Video-Based Coping Skills Training for Caregivers

NCT00396825
View directory record Official record
Conditions
Caregivers
Interventions
Video-based coping skills training with telephone coaching
Behavioral
Lead sponsor
Williams LifeSkills
Industry
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2012 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Not applicable Interventional Results available

Exercise and the Receptor for Advanced Glycation End Products (RAGE)

NCT03534687
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Aerobic Exercise
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042

NCT07222878
View directory record Official record
Conditions
Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions
NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2)
Drug
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
19 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

LifeZig Personalized Reminiscence Video With Slideshows and Music for Individuals With Alzheimer's and Dementia

NCT00759863
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Lifezig
Behavioral
Lead sponsor
Photozig, Inc.
Industry
Eligibility
21 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Moffett Field, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 22, 2026, 6:45 AM EDT
Terminated Phase 2 Interventional Results available

Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

NCT02322021
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Alzheimer Type
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
21
States / cities
Bellflower, California • Costa Mesa, California • Glendale, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 22, 2026, 6:45 AM EDT
Recruiting Not applicable Interventional

Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients

NCT05016219
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Circadian-Effective Light, Rhythmic Light, Placebo Light, Placebo Rhythmic Light
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Menands, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Terminated Phase 2 Interventional Results available

A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

NCT05744401
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AL002
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
15
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Boca Raton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Recruiting Phase 2 Interventional

Daridorexant to Prevent Post-cardiotomy Delirium

NCT07217912
View directory record Official record
Conditions
Postoperative Cognitive Decline, Postoperative Delirium
Interventions
Daridorexant 50 mg, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease

NCT00946530
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
Bright light, Control
Device
Lead sponsor
Stanford University
Other
Eligibility
55 Years to 100 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 22, 2026, 6:45 AM EDT
Terminated Not applicable Interventional

Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid

NCT02343757
View directory record Official record
Conditions
Dementia, Alzheimer Disease
Interventions
PET/MRI
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
21 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 1 Interventional

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease

NCT01966666
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
TPI-287 2 mg/m2, TPI-287 6.3 mg/m2, TPI-287 20 mg/m2, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 82 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Dose Study of COR388

NCT03418688
View directory record Official record
Conditions
Alzheimer Disease
Interventions
COR388, Placebo
Drug
Lead sponsor
Cortexyme Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
San Diego, California • Orlando, Florida • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 22, 2026, 6:45 AM EDT